When considering the combination therapies, none of the low concentration drug combinations resulted in a significant anti-proliferative effect (increased percentage of undivided population, %Undivided %undivided) compared to either NDC or single drug therapies in either AML or normal CD34 + samples (Fig. 4A–F). The gene discussed is CD34; the disease is acute myeloid leukemia.